Logo1
ISLH - 34th Annual International Symposium on Technical Innovations in Laboratory Hematology 2021 (ASCLS/PACE ONLY)
Mr pencil

How would you like your name to appear on your certificate?



What activities did you attend at the event?
Agreement
By completing this form, you attest that you have participated in all selected activities in thier entirety.
Please rate the following:
The program was relevant to my work.
Content matched stated objectives.
Usefulness of handouts/AV/technology.
Quality of facilities and facility accommodations.
How well did the educational sessions give a balanced view of therapeutic options, including the use of generic names?
If you rated any of the above questions with 'fair,' 'poor,' 'disagree,' or 'strongly disagree' please explain in detail (e.g. session title, speaker name, situtation):
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
Objective 1: Define new technological developments in laboratory hematology testing
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
Objective 2: Implement technological advances in the routine hematology laboratory
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
Objective 3: Describe the latest diagnostics capabilities and directions in cellular analysis and flow cytometry
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor used technology effectively
Discuss the laboratory testing and morphologic abnormalities in benign and malignant hematologic diseases.
Discuss the updated findings of coagulation testing in COVID-19 related disease and von Willebrand disease.
Discuss the quality control of molecular laboratory and testing for minimal residual disease by flow cytometry in malignant hematologic diseases.
The instructor used technology effectively
To gain an understanding of the current status of hemophilia gene therapy
To understand how laboratory engagement in the gene therapy process will be required to optimize the efficacy and safety of this new therapeutic modality. 
To assess CAR T cell expansion and function using laboratory parameters
The instructor used technology effectively
Know the recommended initial test set for evaluation of a patient with concern for von Willebrand disease, the criteria for diagnosis of type 1 on Willebrand disease and the influence of aging on diagnosis of type 1 VWD.
Be aware of the existence of type 1C as a subset of patients with type 1 von Willebrand disease and be able to recommend appropriate lab studies to identify these patients.
Understand the advantages and disadvantages of phenotypic and genotypic testing and be able to choose testing for evaluation of patients with type 2 von Willebrand disease.
The instructor used technology effectively
Describe potential applications of clinical cytometry ranging from clinical flow cytometry to multiplexed single-cell morphometry in hematopathology.
Understand the significance of immunophenotypic differences in hematopoietic neoplasms and how they may inform diagnosis or be altered by therapy.
List several contributions of clinical cytometry to diagnosis in hematopoietic neoplasms.
The instructor used technology effectively
Recognize chromatograms and gels from patients who are treated with voxelotor.
Describe how voxelotor interference affects the quantitative reporting of various hemoglobin species
Explain the clinical implications of voxelotor on patient results and clinical management.
The instructor used technology effectively
To discuss quality issues related to the implementation and evaluation of digital morphology.
To discuss challenges and considerations for hemostasis and thrombosis and molecular laboratory testing
To discuss the quality management system as it relates to the hematology laboratory.
The instructor used technology effectively
Understand Supervised machine learning (ML)
Understand how such algorithms can be automated with a mix of unsupervised and supervised ML methods and algorithms, respectively through the MILO Auto-ML platform
Describe how such ML platforms can be used to build predictive analytics tools for Covid-19 testing and stratification
The instructor used technology effectively
Utilizing laboratory methods in the identification of altered oxygen affinity hemoglobin variants.
Utilize a case-based approach to correlate the clinical phenotype with the laboratory identification of hemoglobin variants with altered oxygen affinity.
The participant knowns which NHS methods are applied in hemoglobinopathy diagnostics
The instructor used technology effectively
Review recent molecular findings in myeloid neoplasms
Participants by the end of this presentation should understand how to setup flow cytometric assays to process, strain, analyze, and interpret samples (primarily bone marrow) for plasma cell dyscrasia. Selection of appropriate antibody reagents, choices in panel design (two 8-color tubes versus one 10-color tube), sample preparation (bulk lysis versus pooled tube), and approaches to data analysis will be discussed. The options available and the importance of building a consensus, harmonized approach will be discussed.
Detecting minimal residual disease with sensitivities of 1 cell in 100,000 to 1,000,000 requires a well-designed and validated flow cytometric application. The concepts behind and methods to calculate level of blank, level of detection, and level of quantification will be discussed. Different sensitivities will be correlated with different outcomes in terms of progression free survival and overall survival.
The instructor used technology effectively
Understand the normal physiological changes seen in blood parameters during pregnancy
To know the basic testing required to diagnose anemia during pregnancy
Understand the role of thrombophilia testing during pregnancy
The instructor used technology effectively
Big picture: Why are cold-platelets being re-considered at this point?
Platelet transfusion biology: What happens when we expose platelets to cold temperature? What are the downsides of the platelet “cold-lesion”, are there possible advantages?
Identify different classes of anti-platelet drugs and their mechanism of action
The instructor used technology effectively
Review diagnosis and multiplex technology in NPM1-mutated myeloid disease
Describe the methodological principles of minimal residual disease testing in acute myeloid leukemia.
Recognize the advantages and limitations of different methods for minimal residual disease testing.
The instructor used technology effectively
To illustrate the scientific value of developments in hemocytometry in the last four decades
To appreciate as this is reflected by manuscripts submitted to and published in the International Journal of Laboratory Hematology.
The concept of cell neighborhoods relative to immune function.
The instructor used technology effectively
Learning the multidisciplinary approach to diagnosing and classifying selected challenging hematologic disorders/neoplasms.
Learning the clinical implications of the pathologic and molecular genetic findings and the critical need for clinicopathologic correlation to achieve best clinical outcome.
Learning the clinical implications of the pathologic and molecular genetic findings and the critical need for clinicopathologic correlation to achieve best clinical outcome.
The instructor used technology effectively
Highlight patient and laboratory characteristics that can lead to difficulties diagnosing TTP
Discuss TTP therapies and impact of these therapies on test results
Use a case-based format to review the landscape of ADAMTS13 laboratory testing
Please tell us about any sessions you found particularly good or bad.
Please tell us about any objectives you feel we accomplished well or poorly. 
Please tell us about any presenters you found particularly good or bad.
Please answer the following:
Do you believe this activity was appropriate for the scope of your professional activities?
Was the educational content scientifically sound?
If faculty spoke about off-label or investigational uses of a product, was that information disclosed to you?
Was the mode of education effective to learning?
If you answered "No" to any of the above questions, please explain.
Did you perceive any product/service/company/commercial bias in any educational session you attended or materials you received?
If you answered "Yes" to the above question, please detail the situation below (e.g. session title, speaker name):
Were you solicited by sales personnel in an educational room (other areas do not matter) while you attended this educational activity?
If you answered "Yes" to the above question, please explain in detail (e.g. who, when, where):
How much did you learn as a result of this education program?
What specifically did you learn during this activity that you intend to integrate into your practice?

What questions have arisen in your practice for which you need answers/strategies that you can implement?

What patient/client problems or patient/client challenges do you feel you are not able to address appropriately or to your satisfaction?
What problems are your patients/clients communicating to you that need attention or follow up?

Are you interested in basic, intermediate or advanced level trainings?

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training (the overall meeting) be improved to better impact competence, performance and/or patient/client outcomes?

Additional comments:

How did you attend this course?
Mr question
Provided by amedco